Research > Focus C
Prof. Dr. med. Stefan M. Pfister
Hopp-Children´s Comprehensive Cancer Center at the NCT Heidelberg, Division of Pediatric Neurooncology, DKFZ Heidelberg
The WPs of Focus C in conjunction with the molecular information of Focus A and immunotherapeutic paradigms from Focus B will provide and expand a diagnostic platform, which is capable of coping with the needs of trialists and clinicians for assessment of heterogeneity, real-time non-invasive assessment of response and resistance and the generation of signatures or footprints allowing for personalized treatments. The need for precision and the integration of larger data volumes is managed with interaction of the WPs with D01 & D02. Further, Focus C will provide central data on a drug and biological repository as well as on different radiation qualities (together with B07A) to be used not only in the other WPs but also in further clinical studies. Specific advanced outcomes may be clinical implementation of automated glioblastoma MRI diagnostics and clinical integration of metabolic signatures from UNITE tissues and trial resources as well as globally available tissue resources for validation. From this, further (phase 0) trials may be developed.
Link to: C01: Comprehensive preclinical pharmacology testing of drugs used for glioblastoma treatment
C01
Comprehensive Preclinical Pharmacology Testing of drugs used for glioblastoma treatment
Dr. rer. nat. Gzona Bajraktari-Sylejmani
University Hospital Heidelberg, Department of Clinical Pharmacology and Pharmacoepidemiology
Link to: C02: Radiomics, radiogenomics and deep-learning in neurooncology
C02
Radiomics, Radiogenomics and Deep-Learning in Neuro-Oncology
Prof. Dr. med. Martin Bendszus
University Hospital Heidelberg, Department of Neuroradiology
Prof. Dr. med. Philipp Vollmuth
University Hospital Heidelberg, Department of Neuroradiology
Link to: C03: Imaging immune signatures of glioma response and resistance towards immunotherapy (2019 - 2023)
C03
Imaging IMMUNE signatures of glioma Response and resistance towards immunotherapy (2019-2023)
Dr. med. Michael Breckwoldt
PhD, University Hospital Heidelberg, Department of Neuroradiology
Link to: C04: Metabolic signaling in glioblastoma: a spatial multi-omics approach
C04
Identification and spatial mapping of metabolic resistance factors by MALDI mass spectrometry imaging
Prof. Dr. rer. nat. Carsten Hopf
Hochschule Mannheim, Center for Mass Spectrometry and Optical Spectroscopy
Prof. Dr. med. Christiane Opitz
German Cancer Research Center (DKFZ), Brain Cancer Metabolism Group
Link to: C05: Overcoming glioma radio-resistance with particle therapy
C05
Overcoming glioma radio-resistance with particle therapy
Dr. med. Dr. rer. nat. Amir Abdollahi
University Hospital Heidelberg, Radiationoncology, UKHD
Dr. rer. nat. Ivana Dokic
University Hospital Heidelberg, Radiationoncology, UKHD
Link to: C06: Functional characterization of EGFR structural variants associated with long-term survival in glioblastoma, IDH-WT
C06
Functional characterization of egfr structural variants associated with long-term survival in glioblastoma, IDH-WT
PD Dr. med. David Reuss
University Hospital Heidelberg, Department of Neuropathology
Prof. Dr. med. Andreas von Deimling
University Hospital Heidelberg, Department of Neuropathology